WO2021181415A1 - Procédé de régulation d'isoformes sialylées d'une protéine de fusion fc - Google Patents

Procédé de régulation d'isoformes sialylées d'une protéine de fusion fc Download PDF

Info

Publication number
WO2021181415A1
WO2021181415A1 PCT/IN2021/050233 IN2021050233W WO2021181415A1 WO 2021181415 A1 WO2021181415 A1 WO 2021181415A1 IN 2021050233 W IN2021050233 W IN 2021050233W WO 2021181415 A1 WO2021181415 A1 WO 2021181415A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
tri
protein
salt gradient
isoforms
Prior art date
Application number
PCT/IN2021/050233
Other languages
English (en)
Inventor
Ravichandran Ramakrishnan
Sruba DATTA
Gopinath GOVINDARAJAN
Krishna Prasad Chellapilla
Original Assignee
Dr. Reddy’S Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy’S Laboratories Limited filed Critical Dr. Reddy’S Laboratories Limited
Publication of WO2021181415A1 publication Critical patent/WO2021181415A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to protein purification methods.
  • disclosed is a method for purifying fusion proteins using anion exchange chromatography.
  • Fc-fusion proteins are bioengineered polypeptides that join the crystallizable fragment (Fc) domain of an antibody with another biologically active protein domain to generate a molecule with unique structure-function properties and significant therapeutic potential.
  • the gamma immunoglobulin (IgG) isotype is often used as the basis for generating Fc-fusion proteins because of favorable characteristics such as recruitment of effector function and increased plasma half-life.
  • Fc- fusion proteins Given the range of proteins that can be used as fusion partners, Fc- fusion proteins have numerous biological and pharmaceutical applications, which has launched Fc-fusion proteins into the forefront of drug development.
  • Fc-fusion proteins can be commercially manufactured using platform upstream and downstream methods based for monoclonal antibodies (mAh).
  • receptor domains generally contain one or more glycosylation sites (both N- and O-linked) in contrast to a single glycosylation site for mAbs.
  • the oligosaccharide structures are more varied and complex (complex and high mannose; bi-, tri- and tetra-antennary) in their receptor domains than IgG Fc (complex, bi-antennary) and can contain more sialic acid residues.
  • Presence of large number of sialic acid residues can shift the isolectric point (pi) of Fc-fusion proteins into an acidic pH range and impart significantly more charge heterogeneity on them than that of the conventional mAbs.
  • Glycosylation including sialylation, plays a vital role in protein solubility, stability, serum half-life, activity, and immunogenicity.
  • sialylation is one of the critical attributes affecting the pharmacokinetics of a therapeutic protein and the level of sialic acid can have a significant impact in the phamaco-kinetics (PK) of the Fc-fusion protein molecules.
  • Cytotoxic T-lymphocyte associated protein 4-immunoglobulin (CTLA4-Ig) fusion protein is a highly glycosylated therapeutic fusion protein that contains multiple N- and O- glycosylation sites.
  • CTLA4-Ig fusion protein 3 N-linked sites and one O-linked site were reported rendering the protein to be glycosylated variedly with different glycosylation patterns. While reduced sialylation being an issue, higher sialylation with di-, tri- or tetra-sialylated antennary structured glycosylated pattern are more common in Fc-fusion protein molecules. It becomes essential to obtain optimal sialylation content with a control on the di-, tri- or higher sialylated isoforms, as the level of sialic acid content is known to impact the pharmacokinetics of the protein significantly.
  • the primary objective of the invention is to find a suitable chromatography method to control the di- and tri-sialic acid isoforms in the Fc-protein composition.
  • the present invention discloses a method of controlling the percentage of sialylated isoforms in a composition comprising Fc-fusion proteins, by employing ion exchange chromatography. Particularly, the method, effectively controls di- and tri-sialic acid isoforms of the fusion protein in the fusion protein composition. More specifically, the invention discloses a weak anion-exchange chromatographic method, wherein the elution mode in the chromatographic step is chosen/altered between linear and step gradient to control or obtain the desired amount of di- and tri-sialic acid isoforms in the fusion protein composition. Additionally, the method also provides an increased recovery of the Fc-fusion protein.
  • Fc fusion protein is a protein that contains an Fc region of an immunoglobulin fused or linked to a polypeptide.
  • the heterologous polypeptide fused to the Fc region may be a polypeptide from a protein other than an immunoglobulin protein.
  • the heterologous polypeptide may be a ligand polypeptide, a receptor polypeptide, a hormone, cytokine, growth factor, an enzyme, or other polypeptide that is not a component of an immunoglobulin.
  • Such Fc fusion proteins may comprise an Fc region fused to a receptor or fragment thereof or a ligand from a receptor including, but not limited to, any one of the following receptors: both forms of TNFR (referred to as p55 and p75), Interleukin-1 receptors types I and II (as described in EP Patent No. 0460846, US Patent No. 4,968,607, and US Patent No. 5,767,064, which are incorporated by reference herein in their entirety), Interleukin-2 receptor, Interleukin-4 receptor (as described in EP Patent No. 0 367 566 and US Patent No.
  • Interleukin- 15 receptor Interleukin- 17 receptor
  • Interleukin- 18 receptor granulocyte- macrophage colony stimulating factor receptor
  • granulocyte colony stimulating factor receptor receptors for oncostatin-M and leukemia inhibitory factor
  • receptor activator of NF-kappa B RNK, as described in US Patent No. 6,271,349, which is incorporated by reference herein in its entirety
  • VEGF receptors EGF receptor
  • FGF receptors receptors for TRAIL (including TRAIL receptors 1,2,3, and 4), and receptors that comprise death domains, such as Fas or Apoptosis-Inducing Receptor (AIR).
  • Fc fusion proteins also include peptibodies, such as those described in WO 2000/24782, which is hereby incorporated by reference in its entirety.
  • the composition may be "partially purified” (i.e., having been subjected to one or more purification steps) or may be obtained directly from a host cell or organism producing the antibody (e.g., the composition may comprise harvested cell culture fluid).
  • molar ratio of sialic acids to CTLA4-Ig fusion protein is calculated and given as number of moles of sialic acid molecules per mole of protein (CTLA4-Ig molecules) or dimer. Further, it is referred as mol/mol ratio in the present invention.
  • glycoprotein refers to a protein that is modified by the addition of one or more carbohydrates, including the addition of one or more sugar residues.
  • sialylation refers to the addition of a sialic acid residue to a protein, including a glycoprotein.
  • Sialic acid is a common name for a family of unique nine-carbon monosaccharides, which can be linked to other oligosaccharides. Two family members are N- acetyl neuraminic acid, abbreviated as Neu5Ac or NANA, and N-glycolyl neuraminic acid, abbreviated as Neu5Gc or NGNA. The most common form of sialic acid in humans is NANA.
  • N-acetylneuraminic acid (NANA) is the primary sialic acid species present in CTLA4-Ig molecules.
  • N glycolylneuraminic acid NGNA
  • the method described herein can be used to determine the number of moles of sialic acids for both NANA and NGNA, and therefore levels of both NANA and NGNA are determined and reported for CTLA4-Ig molecules.
  • sialic acid is the terminal residue of both N-linked and O- linked oligosaccharides.
  • di- and tri-sialic acid isoforms refers to the number of sialic acid residues on the N-linked oligosachharaides, wherein di-sialic acid isoforms refers to two and tri-sialic acid isoforms refers to three sialic acid residues terminally attached to N-linked oligosachharides. Further, higher sialic acid isoforms, such as four sialic acid residues terminally attached to N-linked oligosaccharides are referred as “tetra-sialic acid isoforms.” Higher sialylated isoforms includes four or more sialic acid residues terminally attached to N- linked oligosachharides.
  • “High molecular weight aggregates” as referred herein encompasses association of at least two molecules of a product of interest, e.g., Fc-Fusion protein.
  • the association of at least two molecules of a product of interest may arise by any means including, but not limited to, non- covalent interactions such as, e.g., charge-charge, hydrophobic and van der Waals interactions; and covalent interactions such as, e.g., disulfide interaction or no reducible crosslinking.
  • An aggregate can be a dimer, trimer, tetramer, or a multimer greater than a tetramer, etc.
  • Aggregate concentration can be measured in a protein sample using Size Exclusion Chromatography (SEC), a well-known and widely accepted method in the art.
  • Size exclusion chromatography uses a molecular sieving retention mechanism, based on differences in the hydrodynamic radii or differences in size of proteins. Large molecular weight aggregates cannot penetrate or only partially penetrate the pores of the stationary phase. Hence, the larger aggregates elute first and smaller molecules elute later, the order of elution being a function of the size.
  • Mated Mode Chromatography refers to a form of chromatography that uses a chromatographic support with at least two unique types of functional groups, each interacting with the molecule or protein of interest.
  • Mixed mode chromatography generally uses ligands that have more than one type of interaction with target proteins and/or impurities. For example, a charge-charge type of interaction and/or a hydrophobic or hydrophilic type of interaction, or an electroreceptor-donor type interaction. In general, based on the difference in the total interaction, the target protein and one or more impurities can be separated under various conditions.
  • Anion Exchange Chromatography' refers to a form of ion-exchange chromatography that uses a support with functional groups that exchanges anions.
  • the present invention discloses a method of controlling the percentage of sialylated isoforms in a composition comprising Fc-Fusion proteins, wherein the said method comprises use of ion exchange chromatography.
  • the method is used to control the percentage of di- and tri-sialylated isoforms in a composition comprising Fc-fusion proteins, wherein the said method comprises use of weak anion exchange chromatography and the mode of operation is bind and elute.
  • the method is used to control the percentage of di- and tri-sialylated isoforms of an Fc-fusion protein in a composition comprising Fc-fusion proteins, comprising the steps of:
  • composition comprising the Fc-fusion protein and di- and tri-sialylated isoforms on a weak anion exchange chromatography support
  • the conductivity range of the elution buffer solutions used for eluting the protein of interest is between 3 and 22 mS/cm when a linear salt gradient elution is employed and between 12 and 16 mS/cm when a step salt gradient elution is employed.
  • the said method comprises use of one or more chromatographic steps before weak anion chromatography, wherein the preceding chromatography does not comprise an ion exchange chromatography step.
  • the polishing steps may be selected from a group comprising hydrophobic interaction chromatography, ion exchange chromatography, hydrophobic charge induction chromatography and Mixed Mode chromatography.
  • the support used for weak anion exchange chromatography is selected from, Diethylaminoethyl (DEAE), diethyl- (2 -hydroxy-propyl) aminoethyl (QAE) or DEAE Sepharose Fast Flow.
  • anion exchange chromatography is the last chromatographic step for the purification of the said Fc-fusion protein.
  • the method employs use of one or more steps such as viral inactivation, filtration and diafiltration. These steps may be interspersed between the chromatographic steps or after all the chromatographic steps.
  • the Fc-fusion protein is CTLA4-Ig fusion protein.
  • the Fc-fusion protein is abatacept.
  • Example 1 Purification of CTLA4-Ig fusion protein using Weak Anion Exchange Chromatography
  • a CTLA4-Ig fusion protein was cloned and expressed in a Chinese Hamster Ovary cell line and the cell culture broth containing the expressed fusion protein was harvested, clarified and subjected to protein-A affinity chromatography.
  • the eluate from protein-A affinity chromatography was subjected to low-pH incubation and depth filtration, and the obtained eluate was subjected to Hydrophobic Interaction Chromatography that was operated in flow-through mode. Tangential flow filtration (TFF) process was carried out after HIC chromatography to concentrate HIC process output and to exchange the buffer for the next chromatography step.
  • TMF Tangential flow filtration
  • the output of the TFF step comprising the protein of interest was subjected to Mixed Mode Chromatography by loading onto a Ceramic Hydroxyapatite (CHT) resin.
  • CHT Ceramic Hydroxyapatite
  • the flow-through fraction obtained from CHT resin comprising the protein of interest was used as a starting material for the Weak AEX chromatography.
  • the protein of interest in one column was eluted by employing a linear salt gradient elution using an elution buffer of the composition 60 mM tris acetate, 0.2 M NaCl (0 to 100%, 15 column volumes; pH 7.5, conductivity 22 mS/cm).
  • the protein of interest in the other column was eluted by employing a step salt gradient elution using an elution buffer of the composition 60 mM tris acetate, 0.12 M NaCl (pH 7.5, conductivity 14 mS/cm).
  • the outputs of both the columns were collected as fractions based on absorption of ultraviolet light at a wavelength of 280 nm (UV-280 signal) separately and analysed for the percentage of di- and tri-sialic acid isoforms using high performance hydrophilic interaction chromatography (HILIC-EIPLC). Protein recovery using the linear gradient elution was found to be about 70% and using step gradient elution was found to be about 90%. The percentage of di- and tri-sialic acid isoforms in the load and eluate of AEX chromatography employing step gradient elution is shown in Table 1 and the one employing linear gradient elution is shown in Table 2.
  • Table 1 Percentage of di-+tri-sialic acid isoforms in AEX load and AEX eluate in step gradient elution mode
  • Table 2 Percentage of di-+tri-sialic acid isoforms in AEX load and AEX eluate in linear gradient elution mode
  • the eluate from AEX chromatography may then be subjected to one or more ultra/dia filtration steps and buffer exchange steps and/or sterile filtration to obtain a therapeutic composition to be administered for human use.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de purification d'une protéine de fusion Fc à partir de contaminants. Plus particulièrement, le procédé selon l'invention décrit le processus de régulation d'isoformes sialylées d'une protéine de fusion Fc à l'aide d'une chromatographie par échange d'anions. En outre, le procédé décrit l'utilisation soit d'un gradient de sel linéaire soit d'un gradient de sel par pas pour réguler le pourcentage de formes sialylées de la protéine de fusion Fc dans la composition de protéine finale.
PCT/IN2021/050233 2020-03-11 2021-03-10 Procédé de régulation d'isoformes sialylées d'une protéine de fusion fc WO2021181415A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041010284 2020-03-11
IN202041010284 2020-03-11

Publications (1)

Publication Number Publication Date
WO2021181415A1 true WO2021181415A1 (fr) 2021-09-16

Family

ID=77672316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050233 WO2021181415A1 (fr) 2020-03-11 2021-03-10 Procédé de régulation d'isoformes sialylées d'une protéine de fusion fc

Country Status (1)

Country Link
WO (1) WO2021181415A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4118093A4 (fr) * 2020-03-11 2024-04-17 Dr Reddys Laboratories Ltd Procédé de purification d'une protéine de fusion fc

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087184A2 (fr) * 2007-01-17 2008-07-24 Merck Serono S.A. Procédé pour la purification de protéines contenant fc
WO2009053358A1 (fr) * 2007-10-22 2009-04-30 Merck Serono S.A. Procédé de purification de protéines de fusion avec fc
WO2009111347A1 (fr) * 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Protéines hybrides purifiées d’immunoglobuline et leurs procédés de purification
US20190092836A1 (en) * 2005-12-20 2019-03-28 Bristol-Myers Squibb Company Carbohydrate content of ctla4 molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190092836A1 (en) * 2005-12-20 2019-03-28 Bristol-Myers Squibb Company Carbohydrate content of ctla4 molecules
WO2008087184A2 (fr) * 2007-01-17 2008-07-24 Merck Serono S.A. Procédé pour la purification de protéines contenant fc
WO2009053358A1 (fr) * 2007-10-22 2009-04-30 Merck Serono S.A. Procédé de purification de protéines de fusion avec fc
WO2009111347A1 (fr) * 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Protéines hybrides purifiées d’immunoglobuline et leurs procédés de purification

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4118093A4 (fr) * 2020-03-11 2024-04-17 Dr Reddys Laboratories Ltd Procédé de purification d'une protéine de fusion fc

Similar Documents

Publication Publication Date Title
JP6280499B2 (ja) Ｆｃ融合タンパク質の精製方法
US10844103B2 (en) Method for the purification of G-CSF
US20200283472A1 (en) A process for purification of fc-fusion proteins
US20180094023A1 (en) Method for separation of monomeric polypeptides from aggregated polypeptides
MX2009002014A (es) Proceso para la purificacion de proteinas que contienen fc.
KR20120046274A (ko) 항체 생성의 최적화 방법
EP2695889A1 (fr) Purification des protéines par échange d'ions
RU2020127792A (ru) СЛИТЫЕ БЕЛКИ IL-22- Fc И СПОСОБЫ ПРИМЕНЕНИЯ
WO2012160536A1 (fr) Purification d'anticorps
WO2021181415A1 (fr) Procédé de régulation d'isoformes sialylées d'une protéine de fusion fc
JP2020531557A (ja) タンパク質の精製方法
AU2015214245B2 (en) Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2548940A1 (fr) Procede de production de proteines de liaison au facteur de necrose tumorale
WO2021181417A1 (fr) Procédé de purification d'une protéine de fusion fc
WO2021181414A1 (fr) Procédé de séparation d'agrégats de poids moléculaire élevé d'une protéine de fusion fc
WO2001064711A1 (fr) Procede de separation et de purification de proteine
US12018046B2 (en) Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
KR100297927B1 (ko) 인간에리스로포이에틴의정제방법
WO2022234412A1 (fr) Procédé de purification de protéines de fusion fc
Zhao et al. Applications of ion-exchange chromatography for the purification of antibodies
CN118215671A (zh) 一种促红细胞生成刺激蛋白的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21766828

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21766828

Country of ref document: EP

Kind code of ref document: A1